Fortis Healthcare Limited has informed the Exchange about Employee Stock Option Scheme and Amendment to Related Party Policy

Fortis Healthcare's board approved standalone and consolidated unaudited results for Q3 FY26 (ended Dec 31, 2025). Standalone revenue from operations grew to Rs 442.93 crore (up ~20.7% YoY from Rs 366.87 crore), but net profit fell to Rs 28.40 crore (down ~28% YoY from Rs 39.56 crore) due to higher finance costs. For nine months FY26, net profit nearly doubled to Rs 205.37 crore vs Rs 106.02 crore last year. The board also approved a new Employee Stock Option Scheme (ESOP 2026) with a pool of 1,50,99,163 options (about 2% of share capital), subject to shareholder approval, with exercise price equal to market price and a 4-year exercise window. The Related Party Transaction Policy was also revised. Auditor BSR & Co. LLP issued an unmodified limited review report, while drawing attention to ongoing SFIO investigations related to pre-2018 matters and the Supreme Court-directed forensic audit of RHT Health Trust transactions.